Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

5

Revenue 2017

Merck & Co.

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck & Co.'s 2013 sales performance.

Merck

Roche files Tecentriq/Avastin combo in liver cancer

Roche files Tecentriq/Avastin combo in liver cancer

Its combination with Avastin is viewed as a central part of its strategy to gain ground on the leaders in the category, such as Merck &Co/MSD’s Keytruda (pembrolizumab) and

New coronavirus sees drug developers scramble to develop a vaccine

New coronavirus sees drug developers scramble to develop a vaccine Although the early research and development is encouraging, developing a vaccine takes time, with Merck &Co’s Ebola vaccine taking years before it could eventually be widely administered.

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Sanofi completes acquisition of immuno-oncology specialist Synthorx Analysts don’t see Libtayo making a big impression in the field, however – Evaluate Pharma forecasts the drug reaching revenues of just $600m by 2024, far behind Merck &Co’s class

Sarah Matthew named as new Hanover Health Chair

Sarah Matthew named as new Hanover Health Chair Sarah Matthew co-founded Virgo Health in 2003, which grew into one of the leading international healthcare communication agencies.

AZ’s Imfinzi scores orphan drug status in liver cancer

AZ’s Imfinzi scores orphan drug status in liver cancer Merck &Co/MSD. ... AZ is also looking to beat Merck to an approval in small cell lung cancer, one of the only cancers that Keytruda has been unable to show a benefit in.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...
Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...

Infographics